OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its 'ION free' Large Diameter Head Dual Mobility Acetabular ... ( EAST TAUNTON Mass. Nik Nikolaev C...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its 'ION free' Large Diameter Head Dual Mobility Acetabular Cup System

Date:3/10/2010

EAST TAUNTON, Mass., March 10 /PRNewswire/ -- OMNIlife science, Inc., is very pleased to announce that it has entered into an exclusive U.S. distribution agreement with Societe d'Etudes Recherches Fabrication (SERF)-Dedienne Sante of France for its NOVAE® Dual Mobility Acetabular Cup System. OMNI intends to begin distribution of this product in the USA as soon as U.S. FDA approval of the product is achieved.

"Gaining the distribution rights to SERF's NOVAE® line of Dual Mobility Acetabular Cups will allow OMNI to provide its customers with access to large head hip articulation technology that is free from the risk of metal ION release. The SERF Dual Mobility Cup System has a successful clinical history of over 30 years with outstanding implant longevity and extremely low complication rates. Combining this Ion Free, Large Head Dual Mobility Acetabular Cup technology with OMNI's advanced Apex Modular™ and K2 Modular hip stems as well as the new Apex ARC™ Tissue Sparing Hip Stem systems will, upon FDA approval, provide OMNI with the ability to compete against the Metal on Metal large head acetabular cup technology of our competitors without the risks that have recently been associated with Metal on Metal bearing surfaces," said George Cipolletti OMNI's president and CEO.

Nik Nikolaev, Chairman of Orthopaedic Synergy, Inc., the holdi
'/>"/>

SOURCE OMNIlife science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer
3. Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals
4. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
5. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
8. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
9. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
10. NeoMatrix, Inc., Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
11. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. ... analysis systems, announced today that Martin Mulroy ... the Stifel Annual Dental & Veterinary Conference on Wednesday, ... will be held at Le Parker Meridien Hotel in ... About Abaxis Abaxis develops, manufactures, markets and ...

(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ... Changing Regulatory ... the US Market ...

(Date:5/21/2013)... 21, 2013 STAAR Surgical Company (NASDAQ: ... of minimally invasive ophthalmic products, today announced that it ... the Company,s recent financial results and business developments with ... present at the 38 th Annual Deutsche Bank ... at the Westin Waterfront Hotel on Wednesday, May 29, ...

Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4 STAAR Surgical To Present At Upcoming Investor Conferences 2

[0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market [0] STAAR Surgical To Present At Upcoming Investor Conferences

... SHENYANG, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... a leading China-based biotechnology company focused on researching, developing, ... will release its unaudited second quarter 2011 results after ... 2011 at 8:00pm (US Eastern). Following ...

... Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced ... of the U.S. Food and Drug Administration (FDA) ... treatment of moderately to severely active ulcerative colitis ... inadequate response to conventional therapy. REMICADE® was designated ...

Cached Medicine Technology:3SBio Inc. Schedules Unaudited Second Quarter 2011 Results 2 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 2 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 3 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 4 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 5 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 6 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis 7

3SBio Inc. Schedules Unaudited Second Quarter 2011 Results FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...

(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...

(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...

(Date:5/21/2013)... 2013 While North Carolina is synonymous ... travel guides. Brunswick Plantation & Golf Resort is synonymous ... access to 27 holes of "Top10" championship golf. ... Carolina, knowing the Top 10 from an ... the overwhelming task of selecting the course to play. ...

Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2 Health News:Research at the cutting edge of knowledge 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3 Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2

[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis [0] Research at the cutting edge of knowledge [0] Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts [0] Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina

... for diabetes and heart disease, such as high blood ... risk typical of obesity, but they represent only a ... long-term study. The results will be presented Saturday at ... "Some obese persons have a normal cardiovascular risk ...

... ... product line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it ... Rapid Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a ...

... June 2010: Achieving disease remission in patients with ... of socio-economic importance including work productivity and quality ... EULAR 2010, the Annual Congress of the European ... Austrian findings are reported in addition to improvements ...

... ... dedication among healthcare professionals. This awards program salutes the individual health care ... the patients and family members they serve in every sector of the ... Press Club in Washington, D.C., on October 4, where the award winners ...

... for many with low risk disease, researchers find , ... prostate cancer that has a low risk of progression, ... a suitable treatment option, according to a large-scale study ... to treat localized prostate cancer is controversial because, especially ...

... ... Gynecologic Oncologist Mildred Ridgway, MD is now performing a new procedure at Baptist Medical ... Removing uterine fibroids is referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, ...

Cached Medicine News:Health News:Certain obese people are not at high risk of heart disease, diabetes 2 Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2 Health News:Targeting disease remission has socio-economic benefits over low disease activity 2 Health News:Targeting disease remission has socio-economic benefits over low disease activity 3 Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2 Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2 Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2

Certain obese people are not at high risk of heart disease, diabetes Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering Targeting disease remission has socio-economic benefits over low disease activity Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility

For Dermolipectomy or Lipoplasty of upper arms, Lipoplasty of anterior and lateral axillary folds/rolls...

Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....

Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...

Provides gentle compression above and below implants...

Medicine Products:

Arm Bandage Short-Sleeve Bolero Breast Wrap I Diamond Wear™ Subpectoral Implant Stabilizer